BRPI0517207A - composto isolado, metabólito isolado de ciclo {{(e)- e (z)- (2s,3r,4r)-3-hidróxi-4-metil-2-(metilamino)-6,8-nonadien oil}-l-2-aminobutiril-n-metil-glicil-n-metil-l-leucil-l-v alil-n-metil-l-leucil-l-alanil-d-alanil-n-metil-l-leucil- n-metil-l-leucil-n-metil-l-valil} (isa247) e os sais e solvatos farmaceuticamente aceitáveis dos mesmos, método de preparação de metabólitos de isa247 in vitro, método de produção de um metabólito hidroxilado de isa247, metabólito hidroxilado isolado de isa247, metabólito hidroxilado isolado, método de produção de um metabólito de epóxido de isa247 in vitro, metabólito isolado de epóxido de isa247, metabólito isolado de epóxido, método de produção de um metabólito de diol de isa247 in vitro, metabólito de diol isolado de isa247, metabólito de diol isolado, método de produção de um metabólito de diol de isa247, método de produção de um metabólito de diol de isa247 e composição farmacêutica - Google Patents
composto isolado, metabólito isolado de ciclo {{(e)- e (z)- (2s,3r,4r)-3-hidróxi-4-metil-2-(metilamino)-6,8-nonadien oil}-l-2-aminobutiril-n-metil-glicil-n-metil-l-leucil-l-v alil-n-metil-l-leucil-l-alanil-d-alanil-n-metil-l-leucil- n-metil-l-leucil-n-metil-l-valil} (isa247) e os sais e solvatos farmaceuticamente aceitáveis dos mesmos, método de preparação de metabólitos de isa247 in vitro, método de produção de um metabólito hidroxilado de isa247, metabólito hidroxilado isolado de isa247, metabólito hidroxilado isolado, método de produção de um metabólito de epóxido de isa247 in vitro, metabólito isolado de epóxido de isa247, metabólito isolado de epóxido, método de produção de um metabólito de diol de isa247 in vitro, metabólito de diol isolado de isa247, metabólito de diol isolado, método de produção de um metabólito de diol de isa247, método de produção de um metabólito de diol de isa247 e composição farmacêuticaInfo
- Publication number
- BRPI0517207A BRPI0517207A BRPI0517207-1A BRPI0517207A BRPI0517207A BR PI0517207 A BRPI0517207 A BR PI0517207A BR PI0517207 A BRPI0517207 A BR PI0517207A BR PI0517207 A BRPI0517207 A BR PI0517207A
- Authority
- BR
- Brazil
- Prior art keywords
- isa247
- metabolite
- isolated
- methyl
- diol
- Prior art date
Links
- 239000002207 metabolite Substances 0.000 title abstract 22
- 108010057559 voclosporin Proteins 0.000 title abstract 17
- 229960005289 voclosporin Drugs 0.000 title abstract 17
- BICRTLVBTLFLRD-PTWUADNWSA-N voclosporin Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O BICRTLVBTLFLRD-PTWUADNWSA-N 0.000 title abstract 11
- -1 (z) - (2s, 3r, 4r) -3-hydroxy-4-methyl-2- (methylamino) -6,8-nonadien Chemical compound 0.000 title abstract 10
- 238000000034 method Methods 0.000 title abstract 9
- 238000000338 in vitro Methods 0.000 title abstract 6
- 150000002009 diols Chemical class 0.000 title abstract 4
- 150000002118 epoxides Chemical class 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000012453 solvate Substances 0.000 title abstract 2
- 229950003188 isovaleryl diethylamide Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 3
- 238000010189 synthetic method Methods 0.000 abstract 3
- 238000007385 chemical modification Methods 0.000 abstract 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 238000010520 demethylation reaction Methods 0.000 abstract 1
- 239000000284 extract Substances 0.000 abstract 1
- 238000005755 formation reaction Methods 0.000 abstract 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
- 229930182480 glucuronide Natural products 0.000 abstract 1
- 150000008134 glucuronides Chemical class 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 230000033444 hydroxylation Effects 0.000 abstract 1
- 238000005805 hydroxylation reaction Methods 0.000 abstract 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 230000003228 microsomal effect Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 230000019635 sulfation Effects 0.000 abstract 1
- 238000005670 sulfation reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
COMPOSTO ISOLADO, METABóLITO ISOLADO DE CICLO{{(E)- E(Z)-(2S,3R,4R)-3-HIDRóXI-4-METIL-2-(METILAMINO)-6,8- NONADIENOIL} -L-2-AMINOBUTIRIL-N-METIL-GLICIL-N-METIL-L- LEUCIL-L-VALIL-N-METIL-L-LEUCIL-L-ALANIL-D-ALANIL-N-METI L-L-LEUCIL-N-METIL-L-LEUCILI-N-METIL-L -VALIL} (ISA247) E OS SAIS E SOLVATOS FARMACEUTICAMENTE ACEITáVEIS DOS MESMOS, MéTODO DE PREPARAçãO DE METABOLITOS DE ISA247 IN VITRO, MéTODO DE PRODUçãO DE UM METABOLITO HIDROXILADO DE ISA247, METAIBOLITO HIDROXILADO ISOLADO DE ISA247, METABóLITO HIDROXILADO ISOLADO, MéTODO DE PRODUçãO DE UM METABOLITO DE EPóXIDO DE ISA247 IN VITRO, METABOLITO ISOLADO DE EPOXIDO DE ISA247, METABóLITO ISOLADO DE EPóXIDO, MéTODO DE PRODUçãO DE UM METABOLITO DE DIOL DE ISA247 IN VITRO, METABOLITO DE DIOL ISOLADO DE ISA247, METABÈLITO DE DIOL ISOLADO, MéTODO DE PRODUçAO DE UM METABóLITO DE DIOL DE ISA247, MéTODO DE PRODUçãO DE UM METABOLITO DE DIOL DE ISA247 E COMPOSIçAO FARMACêUTICA. Trata-se de metabólitos isolados do análogo de ciclosporina ISA247, incluindo os métodos in vitro para a sua preparação. Os metabólitos compreendem uma modificação química de ISA247, em que a modificação é pelo menos uma reação selecionada do grupo que consiste em hidroxilação, N- desmetilação, formação de diol, formação de epóxido, e ciclização intramolecular, fosforilação, sulf atação, formação de glucuronídeo e glicosilação. Os métodos de preparação incluem métodos semi-sintéticos, nos quais os metabólitos de ISA247 são produzidos a partir dos extratos microssomais das células do fígado de animais, ou de culturas utilizando microorganismos, e métodos completamente sintéticos, tais como a modificação química do composto original ou dos metabólitos isolados empregando métodos sintéticos orgânicos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63739204P | 2004-12-17 | 2004-12-17 | |
| PCT/CA2005/001926 WO2006063470A1 (en) | 2004-12-17 | 2005-12-19 | Metabolites of cyclosporin analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0517207A true BRPI0517207A (pt) | 2008-09-30 |
Family
ID=36587506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0517207-1A BRPI0517207A (pt) | 2004-12-17 | 2005-12-19 | composto isolado, metabólito isolado de ciclo {{(e)- e (z)- (2s,3r,4r)-3-hidróxi-4-metil-2-(metilamino)-6,8-nonadien oil}-l-2-aminobutiril-n-metil-glicil-n-metil-l-leucil-l-v alil-n-metil-l-leucil-l-alanil-d-alanil-n-metil-l-leucil- n-metil-l-leucil-n-metil-l-valil} (isa247) e os sais e solvatos farmaceuticamente aceitáveis dos mesmos, método de preparação de metabólitos de isa247 in vitro, método de produção de um metabólito hidroxilado de isa247, metabólito hidroxilado isolado de isa247, metabólito hidroxilado isolado, método de produção de um metabólito de epóxido de isa247 in vitro, metabólito isolado de epóxido de isa247, metabólito isolado de epóxido, método de produção de um metabólito de diol de isa247 in vitro, metabólito de diol isolado de isa247, metabólito de diol isolado, método de produção de um metabólito de diol de isa247, método de produção de um metabólito de diol de isa247 e composição farmacêutica |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060223743A1 (pt) |
| EP (1) | EP1828229A4 (pt) |
| JP (1) | JP2008524122A (pt) |
| KR (1) | KR20070100284A (pt) |
| CN (1) | CN101120012A (pt) |
| AU (1) | AU2005316095A1 (pt) |
| BR (1) | BRPI0517207A (pt) |
| CA (1) | CA2592343A1 (pt) |
| IL (1) | IL183908A0 (pt) |
| MX (1) | MX2007007262A (pt) |
| TN (1) | TNSN07225A1 (pt) |
| TW (1) | TW200635954A (pt) |
| WO (1) | WO2006063470A1 (pt) |
| ZA (1) | ZA200705475B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004222306A1 (en) | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
| WO2006039163A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Cyclosporin alkyne analogues and their pharmaceutical uses |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| WO2006041631A2 (en) | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| ES2363452T3 (es) * | 2006-07-06 | 2011-08-04 | Ares Trading S.A. | Una composición farmacéutica oral de una anilinopirimidina, su preparación y uso de la misma. |
| US20100094560A1 (en) * | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| EP2151450A1 (de) | 2008-07-29 | 2010-02-10 | Sandoz AG | Verfahren zur Aufarbeitung von mikrobiologisch hergestellten zyklischen Oligopeptiden |
| AU2009276241A1 (en) * | 2008-07-30 | 2010-02-04 | Ciclofilin Pharmaceuticals Corp. | Nonimmunosuppressive cyclosporine analogue molecules |
| CN102803234A (zh) * | 2009-06-02 | 2012-11-28 | 霓坎制药有限责任公司 | 用于治疗疾病的人甲酰基肽受体的拮抗作用 |
| LT2651965T (lt) * | 2010-12-15 | 2019-01-10 | Contravir Pharmaceuticals, Inc. | Ciklosporino analogo molekulės su modifikuotomis 1 ir 3 aminorūgštimis |
| AR090964A1 (es) * | 2012-05-09 | 2014-12-17 | Novartis Ag | Proceso para la elaboracion de undecapeptidos ciclicos |
| AR111963A1 (es) * | 2017-05-26 | 2019-09-04 | Univ California | Método y moléculas |
| CN112218878A (zh) | 2018-04-13 | 2021-01-12 | 北京生命科学研究所 | Ntcp抑制剂 |
| CN110174363A (zh) * | 2019-01-09 | 2019-08-27 | 北京九强生物技术股份有限公司 | 6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途 |
| CN113388002A (zh) * | 2021-06-10 | 2021-09-14 | 梯尔希（南京）药物研发有限公司 | 一种环孢菌素相关化合物的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0296122B1 (en) * | 1987-06-17 | 1993-09-29 | Sandoz Ag | Cyclosporins and their use as pharmaceuticals |
| US5202310A (en) * | 1990-06-06 | 1993-04-13 | Levy Gary A | Cyclosporine metabolites |
| US5834266A (en) * | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| DE69840586D1 (de) * | 1997-10-08 | 2009-04-02 | Isotechnika Inc | Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien |
| US6784156B2 (en) * | 2001-03-05 | 2004-08-31 | Enanta Pharmaceuticals, Inc. | Cyclosporins for the treatment of respiratory diseases |
| DK1436322T3 (da) * | 2001-10-19 | 2008-11-03 | Isotechnika Inc | Blandinger af cyclosporinanaloger og deres anvendelse som immunmodulerende midler |
| DE60231570D1 (de) * | 2001-10-19 | 2009-04-23 | Isotechnika Inc | Synthese von Cyclosporinanalogen |
| US20040110666A1 (en) * | 2002-12-04 | 2004-06-10 | Or Yat Sun | Cyclosporins for the treatment of immune disorders |
| US7012065B2 (en) * | 2003-02-07 | 2006-03-14 | Enanta Pharmaceuticals, Inc. | Cyclosporins for the treatment of immune disorders |
| AU2004222306A1 (en) * | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
| US20040266669A1 (en) * | 2003-06-20 | 2004-12-30 | Wu Frank X. H. | Cyclosporin derivatives for the treatment of immune disorders |
-
2005
- 2005-12-19 BR BRPI0517207-1A patent/BRPI0517207A/pt not_active IP Right Cessation
- 2005-12-19 AU AU2005316095A patent/AU2005316095A1/en not_active Abandoned
- 2005-12-19 WO PCT/CA2005/001926 patent/WO2006063470A1/en not_active Ceased
- 2005-12-19 EP EP05825030A patent/EP1828229A4/en not_active Withdrawn
- 2005-12-19 US US11/313,239 patent/US20060223743A1/en not_active Abandoned
- 2005-12-19 KR KR1020077015724A patent/KR20070100284A/ko not_active Withdrawn
- 2005-12-19 TW TW094144998A patent/TW200635954A/zh unknown
- 2005-12-19 JP JP2007545805A patent/JP2008524122A/ja not_active Withdrawn
- 2005-12-19 CN CNA2005800481960A patent/CN101120012A/zh active Pending
- 2005-12-19 CA CA002592343A patent/CA2592343A1/en not_active Abandoned
- 2005-12-19 MX MX2007007262A patent/MX2007007262A/es not_active Application Discontinuation
-
2007
- 2007-06-13 IL IL183908A patent/IL183908A0/en unknown
- 2007-06-14 TN TNP2007000225A patent/TNSN07225A1/fr unknown
- 2007-07-04 ZA ZA200705475A patent/ZA200705475B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2592343A1 (en) | 2006-06-22 |
| WO2006063470A1 (en) | 2006-06-22 |
| US20060223743A1 (en) | 2006-10-05 |
| IL183908A0 (en) | 2007-10-31 |
| EP1828229A1 (en) | 2007-09-05 |
| AU2005316095A1 (en) | 2006-06-22 |
| TW200635954A (en) | 2006-10-16 |
| EP1828229A4 (en) | 2010-06-30 |
| JP2008524122A (ja) | 2008-07-10 |
| ZA200705475B (en) | 2008-07-30 |
| CN101120012A (zh) | 2008-02-06 |
| MX2007007262A (es) | 2007-10-19 |
| WO2006063470B1 (en) | 2006-08-03 |
| TNSN07225A1 (en) | 2008-11-21 |
| KR20070100284A (ko) | 2007-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0517207A (pt) | composto isolado, metabólito isolado de ciclo {{(e)- e (z)- (2s,3r,4r)-3-hidróxi-4-metil-2-(metilamino)-6,8-nonadien oil}-l-2-aminobutiril-n-metil-glicil-n-metil-l-leucil-l-v alil-n-metil-l-leucil-l-alanil-d-alanil-n-metil-l-leucil- n-metil-l-leucil-n-metil-l-valil} (isa247) e os sais e solvatos farmaceuticamente aceitáveis dos mesmos, método de preparação de metabólitos de isa247 in vitro, método de produção de um metabólito hidroxilado de isa247, metabólito hidroxilado isolado de isa247, metabólito hidroxilado isolado, método de produção de um metabólito de epóxido de isa247 in vitro, metabólito isolado de epóxido de isa247, metabólito isolado de epóxido, método de produção de um metabólito de diol de isa247 in vitro, metabólito de diol isolado de isa247, metabólito de diol isolado, método de produção de um metabólito de diol de isa247, método de produção de um metabólito de diol de isa247 e composição farmacêutica | |
| Van Wagoner et al. | Polyketide biosynthesis in dinoflagellates: what makes it different? | |
| Li et al. | Strategies to diversify natural products for drug discovery | |
| Greshock et al. | Isolation, Structure Elucidation, and Biomimetic Total Synthesis of Versicolamide B, and the Isolation of Antipodal (−)‐Stephacidin A and (+)‐Notoamide B from Aspergillus versicolor NRRL 35600 | |
| Yee et al. | Genome mining of alkaloidal terpenoids from a hybrid terpene and nonribosomal peptide biosynthetic pathway | |
| Rath et al. | Meta-omic characterization of the marine invertebrate microbial consortium that produces the chemotherapeutic natural product ET-743 | |
| Cragg et al. | Impact of natural products on developing new anti-cancer agents | |
| Schrittwieser et al. | The role of biocatalysis in the asymmetric synthesis of alkaloids | |
| Brauers et al. | Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases | |
| Han et al. | Curvulamine, a new antibacterial alkaloid incorporating two undescribed units from a Curvularia species | |
| Tsuda et al. | Scalusamides A− C, New Pyrrolidine Alkaloids from the Marine-Derived Fungus Penicillium c itrinum | |
| GB2428044A (en) | Method of forming mesenchymal stem cells from embryonic stem cells | |
| Watanabe et al. | Recent advances in the chemo-biological characterization of decalin natural products and unraveling of the workings of Diels–Alderases | |
| Huang et al. | Chemical Diversity and Biosynthesis of Drimane‐Type Sesquiterpenes in the Fungal Kingdom | |
| Haynes et al. | Stereochemical elucidation of streptorubin B | |
| El Maddah et al. | Biosynthetic studies of novel polyketides from the marine sponge-derived fungus Stachylidium sp. 293K04 | |
| Guo et al. | Taxonomy driven discovery of polyketides from Aspergillus californicus | |
| Lin et al. | Griseorhodins D–F, neuroactive intermediates and end products of post-PKS tailoring modification in griseorhodin biosynthesis | |
| Parrot et al. | Cyaneodimycin, a bioactive compound isolated from the culture of Streptomyces cyaneofuscatus associated with Lichina confinis | |
| Kita et al. | Bioactive secondary metabolites from symbiotic marine dinoflagellates: Symbiodinolide and durinskiols | |
| He et al. | Structure, derivatization, and antitumor activity of new griseusins from Nocardiopsis sp. | |
| Giddings et al. | Bioactive compounds from extremophilic marine fungi | |
| Charria-Girón et al. | Coprophilous fungi in the search for new antimicrobials and other beneficial natural products | |
| Chang et al. | Pairing comparative genomics with tandem mass-based molecular networking allows to highly efficient discovery of nonribosomal peptides from Nocardia spp. | |
| Cossy | Exiguolide, a simplified analogue of the bryostatins by Nature? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: ISOTECHNIKA INC. (CA) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018070072901/SP DE 01/11/2007. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |